Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
- Sierra Oncology to trade on NASDAQ under the symbol 'SRRA' - - Company to present at the BIOTECH Showcase in San Francisco on January 11th -...
- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 8:00 am on November 17th, 2016 - VANCOUVER, Nov 14, 2016 /PRNewswire/ - ProNAi...
VANCOUVER, Nov. 10, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical stage drug development company focused on advancing...
- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 9:00 am on October 19th, 2016 - VANCOUVER, Oct. 13, 2016 /PRNewswire/ - ProNAi...
- PNT737 currently in Phase 1 clinical trials at the Royal Marsden, London, UK - - Potential to exploit cancer-driving genetic mutations to achieve...
VANCOUVER, Aug. 12, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a drug development company focused on advancing targeted...
- Company provides update on PNT2258 and DNAi platform - VANCOUVER, June 6, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a drug...
VANCOUVER, June 1, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel targeted...
- Small molecule kinase inhibitor AS-141 positioned for clinical trials in 2017 - - CDC7 is an important regulator of DNA replication and DNA damage...
- ProNAi to hold Analyst & Investor Event at 7:00am CT on June 6th - - ProNAi to Present at Jefferies 2016 Healthcare Conference in New York on June...
VANCOUVER, May 10, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel therapeutics for...
- Company opens San Francisco area office - VANCOUVER, March 18, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage...
VANCOUVER, March 14, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel therapeutics for ...
VANCOUVER, March 3, 2016 /PRNewswire/- ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel therapeutics for...
VANCOUVER, Dec. 22, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of...
VANCOUVER, Dec 18, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of...
VANCOUVER, Dec 3, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of...
VANCOUVER, Nov. 11, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of...
VANCOUVER, Nov. 5, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of...
- First patient dosed in clinical trial evaluating DNAi interference (DNAi®) - VANCOUVER, Oct. 29, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc....
Completed Upsized Initial Public Offering, Raising Gross Proceeds of $158.4 Million Advanced Clinical Programs for PNT2258 in DLBCL and Richter's...
VANCOUVER, July 21, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of...
VANCOUVER, July 15, 2015 /PRNewswire/ - ProNAi Therapeutics, Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based...
VANCOUVER, June 23, 2015 /PRNewswire/ - ProNAi Therapeutics Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based on ...
VANCOUVER, June 18, 2015 /PRNewswire/ - ProNAi Therapeutics, a clinical-stage oncology company pioneering a novel class of therapeutics based on its...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.